Obesity Clinical Trial
— SuperWINOfficial title:
Supermarket and Web-Based Intervention Targeting Nutrition (SuperWIN) for Cardiovascular Risk Reduction
NCT number | NCT03895580 |
Other study ID # | 20168163 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | April 8, 2019 |
Est. completion date | August 31, 2021 |
Verified date | February 2022 |
Source | University of Cincinnati |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The Supermarket and Web-based Intervention targeting Nutrition (SuperWIN) for cardiovascular risk reduction is a novel, randomized controlled trial aimed at increasing diet quality and decreasing cardiovascular risk. SuperWIN will deliver individualized, nutrition education at the point-of-purchase (POP), either in the aisles of the physical store or via online shopping platforms coupled with other modern software tools.
Status | Completed |
Enrollment | 267 |
Est. completion date | August 31, 2021 |
Est. primary completion date | June 6, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 21 Years to 75 Years |
Eligibility | Inclusion Criteria: 1. Age =21 to =75 years on the start date of the study (Day 0) 2. Speak, write, read English fluently 3. In-person outpatient visit with a UC Health primary care network (PCN) provider within the last 12 months 4. Major food planner of their household, which may include planning, purchasing, and/or preparing greater than 50% of the meals or foods consumed at home 5. Existing shopper at a study site Kroger (=50% of grocery store food dollars spent at Kroger) with a Kroger Loyalty ID number 6. Willing to use a new individual Kroger Loyalty ID number for the duration of the study 7. Access to a home desktop or laptop computer with reliable internet access 8. Access to an email account that can be used for the duration of the study 9. Able to independently purchase and prepare food: 1. Reliable transportation to participating Kroger store 2. Ability to stand for significant periods of time to grocery shop and prepare food at home 3. Tools and equipment needed to prepare own food at home, such as a kitchen equipped with basic cooking tools (e.g. burner, pan, spatula, sink) 10. Presence of a cardiovascular risk factor(s) (at least one): 1. Hypertension (defined by one of the following): - Blood pressure measurement: systolic blood pressure (SBP) 130-189 mm Hg and/or diastolic blood pressure (DBP) 80-109 mm Hg (at Visit #1) - Current treatment with an oral medication prescribed by a physician for blood pressure lowering (defined by one of the following): 1. Beta blockers 2. Diuretics (e.g. thiazide or thiazide-like diuretics, loop diuretics, aldosterone antagonists, potassium-sparing diuretics) 3. Angiotensin-converting enzyme inhibitors 4. Angiotensin II receptor blockers 5. Direct renin inhibitors (i.e. aliskiren) 6. Calcium channel blockers (dihydropyridine and nondihydropyridine) 7. Calcium alpha2-agonist and other centrally acting drugs (e.g. clonidine) 8. Direct vasodilators (e.g. hydralazine) 2. Body-mass index (BMI) measurement =30 kg/m2 (at Visit #1) 3. Hypercholesterolemia (defined by one of the following): - Low density lipoprotein cholesterol (LDL-C) 130-189 mg/dl (at Visit #1) - Current treatment with a medication prescribed by a physician for hypercholesterolemia (defined by one of the following): 1. Statins 2. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors 3. Absorption inhibitors (i.e. ezetimibe) 4. Fibrates 5. High-dose niacin (=1 g per day) 6. Bile acid sequestrants (e.g. cholestyramine) Exclusion Criteria: 1. Unwillingness or inability to modify current diet 2. Actively engaged in another dietary intervention or taking a weight-loss supplement 3. SBP =190 mm Hg or DBP =110 mm Hg (at Visit #1) 4. Low-density lipoprotein cholesterol (LDL-C) =190 mg/dl, triglycerides (TG) =600 mg/dl, or glucose =400 mg/dl (at Visit #1) 5. Evidence of prior diagnosis of severe chronic kidney disease (CKD) defined by electronic health record codes for dialysis, CKD Stage 4 or 5 and/or last estimated glomerular filtration rate (eGFR) =30 ml/min/1.732 [based on Modification of Diet in Renal Disease (MDRD) formula] 6. Active cancer other than non-melanoma skin cancers (i.e. basal cell carcinoma or squamous cell carcinoma) 7. Diagnosis of celiac disease, ulcerative colitis, or Crohn's disease 8. High risk for alcohol use disorder: 1. =21 drinks a week (men) 2. =14 drinks a week (women) 9. Women who are pregnant or plan to become pregnant within the next 6 months from the start of the study (Day 0) 10. Food allergies requiring a specialized diet, including allergies to dairy products, eggs, peanuts, tree nuts, soy, gluten-containing wheat and grains, fish, and shellfish 11. Previous visit at TLC for diet counseling 12. Previous use of the Kroger's online shopping platform (Kroger.com or the Kroger app) 13. Participant lives greater than 20 miles from any participating Kroger study store (defined by zip codes) 14. Women, Infants, and Children (WIC) beneficiaries in their household |
Country | Name | City | State |
---|---|---|---|
United States | University of Cincinnati Medical Center - UC Health | Cincinnati | Ohio |
Lead Sponsor | Collaborator |
---|---|
University of Cincinnati | Children's Hospital Medical Center, Cincinnati, The Kroger Company |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Change in waist circumference | Measured. Units: cm | Baseline with follow-up measures at 90 days and 180 days. | |
Other | Change in food literacy | Assessed by participant survey. | Baseline with reassessment at 90 days. | |
Other | Participant experience and feedback | Assessed by participant survey. | Collected at 90 days. | |
Other | Dietitian experience and feedback | Assessed by dietitian survey. | Collected at 90 days. | |
Primary | Change in Dietary Approaches to Stop Hypertension (DASH) score | The DASH score will be calculated from food group analyses obtained from means of three 24-hour dietary intake recalls at each time-point. This DASH score is a 90-point continuous score used to measure change in overall dietary quality in response to an intervention. Given that the dietary focus of the SuperWIN interventions is the DASH dietary pattern, the DASH score will be used as a measure of adherence to a DASH eating pattern. Higher values indicate greater adherence. | Baseline with follow-up measures at 90 days and 180 days. Primary tests are between baseline and 90 day timepoint. | |
Secondary | Change in systolic arterial blood pressure | Measured in the arm. Units: mm Hg | Baseline with follow-up measures at 90 days and 180 days. | |
Secondary | Change in diastolic arterial blood pressure | Measured in the arm. Units: mm Hg | Baseline with follow-up measures at 90 days and 180 days. | |
Secondary | Change in body mass index | Height and weight measured. Units: kg/m2 | Baseline with follow-up measures at 90 days and 180 days. | |
Secondary | Change in non-high density lipoprotein cholesterol (Non-HDL-C) | Total cholesterol minus HDL-C. Units: mg/dL | Baseline with follow-up measures at 90 days and 180 days. | |
Secondary | Change in total cholesterol | Measured. Units: mg/dL | Baseline with follow-up measures at 90 days and 180 days. | |
Secondary | Change in triglycerides | Measured. Units: mg/dL | Baseline with follow-up measures at 90 days and 180 days. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |